Great Lakes Advisors LLC Cuts Stock Holdings in Insulet Corporation $PODD

Great Lakes Advisors LLC reduced its position in shares of Insulet Corporation (NASDAQ:PODD) by 7.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,230 shares of the medical instruments supplier’s stock after selling 248 shares during the period. Great Lakes Advisors LLC’s holdings in Insulet were worth $848,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its stake in Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock worth $1,376,000 after buying an additional 1,867 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Insulet by 85.1% in the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 412 shares in the last quarter. QRG Capital Management Inc. lifted its stake in Insulet by 75.6% in the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier’s stock worth $533,000 after purchasing an additional 874 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Insulet by 225.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier’s stock worth $408,000 after purchasing an additional 1,075 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in Insulet by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier’s stock worth $2,156,000 after purchasing an additional 210 shares in the last quarter.

Insulet Stock Performance

Insulet stock opened at $337.94 on Friday. The firm has a 50 day simple moving average of $310.77 and a 200-day simple moving average of $291.47. Insulet Corporation has a 1-year low of $225.28 and a 1-year high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The stock has a market cap of $23.79 billion, a price-to-earnings ratio of 102.72, a price-to-earnings-growth ratio of 2.80 and a beta of 1.36.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s revenue was up 32.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Insulet in a research note on Friday, May 30th. They issued a “buy” rating and a $380.00 target price on the stock. Raymond James Financial reissued an “outperform” rating and issued a $360.00 target price (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Barclays raised their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Finally, Oppenheimer increased their price target on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday. Sixteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $335.12.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.